Sign in
Taking peoplePhase 2

Efficacy of Reboxetine and Methylphenidate Treatment on Attentional, Sensory and Emotional Dysregulation in Adults With PTSD

Key facts

Who runs it
University of Haifa
Where
Israel3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
53 people, planned
Started
1 Jun 2022
Expected to end
1 Dec 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Methylphenidate
  • Reboxetine
  • Placebo
Record updated
11 August 2026

Who can take part

Age
20 years to 60 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • diagnosed with PTSD according to DSM-IV or DSM-5 criteria
  • current treatment at the outpatient facilities of Lev HaSharon Netanya Adult Clin
  • age between 20 and 60 years
  • PTSD diagnosis at least one month prior to study inclusion
  • no present-day re-exposure to the traumatic event
  • any psychotropic drug therapy that is being administered must be at a fixed dose for at least one month prior to the study conductance

Who cannot take part

  • previous or current severe traumatic brain injury,
  • use of steroid medication in the two months prior to study conductance,
  • use of medication that may affect the function of the central nervous system,
  • comorbid major psychiatric disorder, e.g. psychotic disorder, unipolar or bipolar disorder, borderline personality disorder, or active suicidal ideation,
  • significant or severe systematic disease that limits normal activity, e.g. autoimmune disease, AIDS or renal failure,
  • cardiovascular disease, e.g. hypertension, atrioventricular (AV) block, bradycardia, or conduction disorder,
  • severe disease that is a threat to life, e.g. acute myocardial infarction, respiratory failure, or cancer,
  • nervous system impairment, e.g. multiple sclerosis, Alzheimer's disease, Parkinson's disease, epilepsy, or stroke,
  • failure to complete all research steps
  • ADHD diagnosis,
  • glaucoma,
  • impaired hearing,
  • pregnancy or breastfeeding during study inclusion,
  • active substance dependency including regular use of medical cannabis,

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 20 and 60 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Up-to-date, no studies have examined the attentional, sensory and emotional processing (difficulties) among patients diagnosed with Posttraumatic Stress Disorder (PTSD). In addition, the efficiency of drug treatments that focus on the noradrenergic and dopaminergic, and thus influence attention processing and PTSD symptoms through these pathways, have only briefly been investigated. There is well-established and long-standing evidence for the involvement of dopamine and noradrenaline in attentional function. This previously led to an investigation by the investigator's research lab in which the investigators hypothesized the involvement of an attentional disorder would influence PTSD symptoms in a rat model. Based on these results, the current study aims to characterize attentional deficits in patients with PTSD, as well as the correlation between attention, emotional regulation and sensory processing. The investigators do this partially by conducting a case-control study and through a subsequent double-blind RCT (with only the cases). The patients will be either treated with reboxetine + methylphenidate or placebo.

The 2 groups in the trial

  • Treatment with Reboxetine and MethylphenidateTreatment being tested

    During the first 3 weeks of the study, subjects in the active treatment group will take reboxetine at a dose of 4mgper day, with the instructions to start at 2mg per day for 3 days and then increase the dosage to 4mg per day for 26 days, i.e. until completion of the study. On day 22 of the study, the patients will take the first dosage of10mg Ritalin or a placebo, and remain in the clinic for 2 hours to guard safety and guidance during possible occurrence of side effects such as anxiety, palpitations, etc. During the observation time in the clinic, 6 Ritalin IR 10mg and 3 Reboxetine 4mg pills will be handed out to the participants. These pills will be taken at the responsibility of the subject at8:00 AM (Ritalin and Reboxetine) and at noon (Ritalin only) at the following three days.

    Treatment: Methylphenidate and Reboxetine

  • Treatment with PlaceboPlacebo, for comparison

    The patients will take placebos according to the medication schedule of the treatment group.

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
The Relation Between Attentional, Sensory and Emotional Dysregulation in Adults With Posttraumatic Stress Disorder: a Double-blind, Placebo-controlled Randomized Controlled Trial of the Combined Treatment With Reboxetine and Methylphenidate
Fit questions
Built from NCT05133804, who can take part
Record updated
11 August 2026